

1 Identification of a specific APOE transcript and functional elements associated with Alzheimer's  
2 disease

3  
4 Qiang Chen<sup>1</sup>, Luis Aguirre<sup>2</sup>, Huanhuan Zhao<sup>3</sup>, Felix Borrego<sup>2</sup>, Itziar de Rojas<sup>4,5</sup>, Lingyan Su<sup>6</sup>,  
5 Pan P. Li<sup>7</sup>, Bao Zhang<sup>8</sup>, Erzsebet Kokovay<sup>9</sup>, James D Lechleiter<sup>9</sup>, Harald H. Göring<sup>10</sup>, Philip L.  
6 De Jager<sup>11</sup>, Joel E. Kleinman<sup>1,7</sup>, Thomas M. Hyde<sup>1,7</sup>, Agustín Ruiz<sup>2,4,5</sup>, Daniel R.  
7 Weinberger<sup>1,7,12</sup>, Sudha Seshadri<sup>2,13,14\*</sup>, Liang Ma<sup>2,15\*</sup>

- 8  
9 1. Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD,  
10 USA  
11 2. Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas  
12 Health Science Center at San Antonio, San Antonio, TX, USA  
13 3. Bioinformatics Program, University of Texas at El Paso, TX, USA  
14 4. Research Center and Memory Clinic. Ace Alzheimer Center Barcelona – Universitat  
15 Internacional de Catalunya, Barcelona, Spain  
16 5. Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute  
17 of Health Carlos III, Madrid, Spain  
18 6. College of Food Science and Technology, Yunnan Agricultural University, Kunming, Yunnan,  
19 China  
20 7. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of  
21 Medicine, Baltimore, MD, USA  
22 8. College of Forensic Medicine, Xi'an Jiaotong University Health Science Center, Xi'an,  
23 Shaanxi, China  
24 9. Department of Cell Systems and Anatomy, University of Texas Health Science Center at San  
25 Antonio, San Antonio, Texas, USA  
26 10. Department of Human Genetics and South Texas Diabetes and Obesity Institute, University  
27 of Texas Rio Grande Valley School of Medicine, San Antonio, TX, USA  
28 11. Center for Translational and Computational Neuroimmunology, Department of Neurology,  
29 Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of  
30 Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA  
31 12. Departments of Neurology, Neuroscience, and Genetic Medicine, Johns Hopkins University  
32 School of Medicine, Baltimore, MD, USA  
33 13. Department of Neurology, University of Texas Health Science Center at San Antonio, San  
34 Antonio, TX, USA  
35 14. Department of Neurology, Boston University School of Medicine, Boston, MA, USA  
36 15. Department of Pharmacology, University of Texas Health Science Center at San Antonio,  
37 San Antonio, TX, USA

38  
39 \*Corresponding Author:  
40 Email: Liang Ma, PhD, [mall@uthscsa.edu](mailto:mall@uthscsa.edu); Sudha Seshadri, MD, [Seshadri@uthscsa.edu](mailto:Seshadri@uthscsa.edu).  
41 Mailing address: Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases,  
42 University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio,  
43 TX 78229  
44 Phone: 210-450-3077

1 ABSTRACT

2 INTRODUCTION.

3 The *APOE* gene is the strongest genetic risk factor for late-onset Alzheimer's Disease (LOAD).  
4 However, the gene regulatory mechanisms at this locus have not been fully characterized.

5  
6 METHODS.

7 To identify novel AD-linked functional elements within the *APOE* locus, we integrated SNP  
8 variants with RNA-seq, DNA methylation, and ChIP-seq data from human postmortem brains.

9  
10 RESULTS.

11 We identified an AD-linked *APOE* transcript (*jxn1.2.2*) observed in the dorsolateral prefrontal  
12 cortex (DLPFC). The *APOE jxn1.2.2* transcript is associated with brain neuropathological features  
13 in DLPFC. We prioritized an independent functional SNP, rs157580, significantly associated with  
14 *jxn1.2.2* transcript abundance and DNA methylation levels. rs157580 is located within active  
15 chromatin regions and predicted to affect brain-related transcriptional factors binding affinity.  
16 rs157580 shared the effects on the *jxn1.2.2* transcript between European and African ethnic groups.

17  
18 DISCUSSION.

19 The novel *APOE* functional elements provide potential therapeutic targets with mechanistic  
20 insight into the disease's etiology.

21  
22  
23 KEYWORDS: *APOE*; Alzheimer's disease; transcript; ChIP-seq; DNA methylation; postmortem  
24 brain

25  
26  
27  
28  
29

## 1 INTRODUCTION

2 Alzheimer's disease (AD) is a devastating neurodegenerative disease characterized pathologically  
3 by the accumulation of amyloid- $\beta$  plaques and tau tangles, which leads to neuronal cell death and  
4 cognitive impairment. Most AD cases are non-Mendelian and late-onset ( $> 65$  years old), and there  
5 is only limited treatment to slow down cognitive decline (e.g., lecanemab<sup>1</sup>), making AD the  
6 leading cause of mortality in the aging population<sup>2</sup>. African Americans remain underrepresented  
7 in AD research, despite the prevalence of AD being possibly double in frequency in AA compared  
8 to European Ancestry individuals<sup>3</sup>.

9  
10 The human *APOE* protein has three common isoforms defined by two single nucleotide  
11 polymorphisms (SNPs) that reside in the coding region of exon 4. Of note, the apolipoprotein E  
12 gene (*APOE*) epsilon 2 (*APOE2*) and epsilon 4 (*APOE4*) alleles are two major genetic risk factors  
13 for late-onset AD. Compared to the commonest genotype (homozygous genotype comprising two  
14 copies of the *APOE* epsilon 3 *APOE3/3*), people carrying two *APOE4* alleles (homozygotes) are  
15 at the highest risk<sup>4</sup>. Yet, there is no therapeutic intervention to reduce this risk of *APOE4* carriers.  
16 Therefore, uncovering and understanding biological effects regulating the expression of *APOE*  
17 isoforms might contribute to the control of this important AD risk factor.

18  
19 Recently, we performed genome-wide association studies (GWAS)<sup>5</sup> and identified many AD-risk  
20 SNPs within the *APOE* gene region (**Supplementary Fig. S1**). However, most of these identified  
21 signals are in non-coding regions and are in complex linkage disequilibrium (LD) with other  
22 variants, including the SNPs encoding for the protein isoforms of *APOE*. Although we suspect the  
23 existence of additional variants modulating the risk of *APOE* isoforms, the complexities within  
24 the locus might present difficulties in elucidating their potential modulation of AD-related risk  
25 alleles. Cis-acting expression quantitative trait loci (eQTLs) studies might help to improve our  
26 understanding of the mechanisms of AD-associated variants in the regulation of the *APOE* gene  
27 expression<sup>6,7</sup>. Interestingly, a splicing variant of *APOE* mRNA with intron-3 retention, a long non-  
28 coding RNA, was found to govern *APOE* gene expression in neurons<sup>8</sup>. Furthermore, this non-  
29 coding RNA of *APOE* is more abundant in AD with more severe tau and amyloid pathological  
30 burden<sup>9</sup>. In contrast, we still do not know the roles of each *APOE* protein-coding transcript in AD  
31 pathogenesis. A study between *APOE* transcription and AD pathology has been attempted in AD  
32 brains from the superior temporal gyrus, but no significant correlation was determined<sup>10</sup>.

33  
34 Another challenge is to understand the specific mechanism(s) by which variations at the *APOE*  
35 locus alter risk, including DNA methylation, chromatin activity, transcriptional factors (TFs)  
36 binding, and their interaction with SNPs and specific *APOE* transcripts. Level changes of DNA  
37 methylation were observed in AD subjects in the *APOE* CpG islands within exon 4 compared to  
38 age-matched controls in brain tissue<sup>11</sup>. Chip-seq of histone marks has been generated at the *APOE*  
39 locus from several studies<sup>12</sup>. However, how common risk alleles influence the epigenetic elements  
40 in AD remains largely unknown.

41  
42 The present study aims to connect common AD risk alleles at the *APOE* locus with transcript(s),  
43 CpGs, and active chromatin regions by combining available human postmortem brain high-  
44 throughput functional genomics data. We leveraged two large human autopsy brain cohorts  
45 collected by the Religious Orders Study/Memory and Aging Project (ROSMAP)<sup>13</sup> and the Lieber  
46 Institute for Brain Development (LIBD)<sup>14</sup>. Overall, we deepen our understanding of genetic and

1 epigenetic regulation of *APOE* in the postmortem brain and provide a foundation for formulating  
2 mechanistic hypotheses for the variants within *APOE* associated with AD risk.

3

## 4 RESULTS

5 To elucidate the mechanism of AD risk variants and its connections with transcriptomic, genetic,  
6 and epigenetic features within the context of AD, we harnessed the power of available multi-omics  
7 datasets sourced from diverse brain regions and two ancestries (**Fig. 1A**). It is noteworthy that  
8 while certain facets of this dataset have previously been analyzed in studies exploring brain  
9 phenotypes<sup>15,16</sup>, these earlier investigations predominantly emphasized genome-wide patterns. In  
10 contrast, our current study is distinct in its focus to unravel the intricate regulatory mechanisms  
11 operating within the *APOE* locus. As a novel contribution, we present, for the first time,  
12 compelling associations between AD-associated risk SNPs and important functional elements at  
13 the *APOE* locus.

14

15 Our investigative journey commenced with a comprehensive exploration of the *APOE* locus,  
16 extracting transcriptomic, methylation, and histone modification features from the ROSMAP  
17 dorsolateral prefrontal cortex (DLPFC) dataset (see data availability). Serving as our cornerstone,  
18 this brain region formed the basis for probing *APOE* gene expression, encompassing bulk tissue  
19 RNA-seq (n = 655), histone modification through H3K9ac ChIP-seq (n = 615), and DNA  
20 methylation utilizing the 450K Illumina array (n = 667). Applying a congruent methodology, the  
21 LIBD dataset (see Methods) became another vital resource for investigation. With the DLPFC  
22 brain region at its core, this dataset facilitated the accumulation of additional bulk RNA-seq data  
23 from African Americans (n = 216).

24

25 Because the vast majority of genes are regulated within an enhancer's chromosomal position (cis-  
26 regulation), we limited our transcriptional mechanism studies to 2 Mb<sup>17</sup> spanning the *APOE* gene.  
27 To select potential functional variants in the selected region, we extracted the genotypes of 6,428  
28 high-quality SNPs from ROSMAP whole-genome sequencing data, and 10,838 SNPs from LIBD  
29 African for downstream analysis.

30

31 *APOE* jxn1.2.2 transcript is uniquely linked to specific AD risk-associated alleles in the *APOE*  
32 region.

33 To pinpoint *APOE*'s mRNA transcripts within specific gene regions, we employed an expression  
34 feature known as exon-exon junctions. This approach effectively tags specific transcripts,  
35 enhancing our ability to quantify them with a heightened degree of precision and specificity, as  
36 demonstrated by our recent postmortem brain studies<sup>18-20</sup>. Following the reads alignment and  
37 quality controls, our efforts yielded three distinct splicing junctions connecting exon 1 and exon 2,  
38 alongside a common junction spanning exon 2 and exon 3, as well as another common junction  
39 bridging exon 3 to exon 4 (**Fig. 1B**). Consequently, our focus homed in on the junction linking  
40 alternative exons 1 and 2, a pivotal choice given its capacity to delineate diverse *APOE* transcripts.  
41 Then, we combined the *APOE* gene expression information with genomic variants previously  
42 selected with the aim to identify the SNPs associated with the levels of the *APOE* transcripts  
43 identified. Specifically, we examined the association of selected variants with the global  
44 abundance of *APOE* expression (combining reads of all transcripts identified) as well as the  
45 abundance of each different spliced isoform. To this end, we initially adjusted the dependent

1 variables by ancestry and potential batch effects by regressing the expression levels with five  
2 ancestry principal components (PCs) derived from sequencing data and K PCs to correct potential  
3 batch effects detected by sva<sup>21</sup> (detailed in Methods). The Adjusted expression levels were then fit  
4 to SNP genotypes, covarying for sex and diagnosis, using an additive linear model implemented  
5 in TensorQTL<sup>22</sup>. Across the RNA-seq datasets (**Fig. 1A**), we identified an average of 57k SNP-  
6 gene pairs and 5M SNP-junction pairs at the *APOE* locus, about 6k and 12k cis-eQTLs at gene  
7 and junction levels with a false discovery rate (FDR) < 0.05.

8  
9 To link the *APOE* transcripts-associated variants (eQTLs) to AD risk alleles, we co-localized  
10 observed eQTLs with AD GWAS<sup>5</sup> SNPs (**Supplementary Fig. S1**). The integration yields an  
11 average of 355 SNP-gene pairs and 586 SNP-junction pairs with genome-wide significance for  
12 AD risk ( $p < 5e-8$ ) and FDR-significant for eQTL analysis (FDR < 0.05). Importantly, we uncover  
13 that a particular junction between alternative exon 1 and exon 2 (named jxn1.2.2 and tagging the  
14 *APOE* transcript NM\_001302688) is the top hit junction at the *APOE* locus co-localizing with  
15 variants associated with AD-risk ( $p = 1.71e-13$ ) (**Fig. 1B and 2A**). We didn't observe statistical  
16 significance between AD risk variants (GWAS  $p < 5e-8$ ) and other *APOE* transcripts (jxn1.2.1 and  
17 jxn1.2.3) or *APOE* gene-wide expression level (**Fig. 2B**).

18  
19 To assess the potential influence of ancestry on the relationship between *APOE* jxn1.2.2 transcripts  
20 and AD genome-wide significant risk alleles ('AD alleles' hereafter), we also conducted an  
21 analysis of RNA-seq data from the LIBD African ancestry brain DLPFC collections, and this  
22 association persists (**Fig. 2C**), suggesting a significant link between *APOE* jxn1.2.2 transcripts and  
23 AD alleles in samples from two different ancestries. Because we analyze European and African  
24 ancestries separately, the local ancestry may not be representative for the whole heterogeneity  
25 among ancestries. Instead, we performed global ancestry analysis using the Identity by Decent  
26 (IBD) test and Principal Component Analysis (PCA) by integrating genotype data of ROSMAP  
27 and LIBD separately with HapMap3 populations (see Methods and **Supplementary Fig. S2**).

28  
29 The gene structure of *APOE* consists of four exons, with the two SNPs (rs429358 and rs7412  
30 located in exon 4) determining the three common protein isoforms of the *APOE* gene (**Fig. 1B**).  
31 To determine if the association of AD alleles with jxn1.2.2 transcript is independent of the  
32 APOE2,3,4 alleles, we performed the conditional analysis by including the APOE2,3,4 defining  
33 SNPs as co-variants, and found the results were not influenced in independent datasets: ROSMAP  
34 European and LIBD African populations (**Supplementary Fig. S3**). To further define the  
35 independent effects of our candidate AD alleles on APOE jxn1.2.2 expression from APOE  
36 genotypes, we performed epistasis (statistical interaction analysis), and we did not observe  
37 significant interactions between our candidate AD alleles and the APOE4 and APOE2 alleles  
38 (**Supplementary Table S1**), indicating the association between jxn1.2.2 expression and our  
39 candidate AD-risk alleles is not influenced by APOE4. The independent expression of jxn1.2.2  
40 transcript was further supported by the lack of association between APOE2,3,4 determining SNPs  
41 and jxn1.2.2 expression (**Supplementary Table S1**).

42  
43 *APOE* jxn1.2.2 transcript expression levels are associated with AD pathology in DLPFC.

44 To explore the role of *APOE* transcripts abundance in AD, we compared its expression level  
45 between AD and controls using different AD endophenotype Braak criterion to evaluate the  
46 density and distribution of neurofibrillary tangles (NFT)<sup>23,24</sup>. At the gene level by combining all

1 transcripts, the *APOE* expression was not differentially expressed in DLPFC brain region. At the  
2 single transcripts level, by analyzing the three transcripts separately, we found that jxn1.2.2  
3 transcript was differentially expressed between AD and controls compared to other *APOE*  
4 transcripts (jxn1.2.1 and jxn1.2.3) in DLPFC (**Fig. 3**).

5  
6 *Identifying functional SNPs using epigenetic data from brain tissues.*

7 To identify potential regulatory SNPs in the *APOE* region, we carried out a rigorous statistical  
8 effort to identify CpGs spanning the *APOE* region. We obtained 777 CpG sites and performed  
9 association analysis between 7,335 SNPs and methylation levels in selected epigenetic features  
10 (mQTL). After filtering with mQTL FDR < 0.05, we obtained 5,029 SNPs and 312 CpG sites.  
11 Subsequently, to link the DNA methylation with AD, we integrated selected CpG sites with AD  
12 variants and eQTL results. We observed significant impacts of AD alleles of rs157580 on DNA  
13 methylation cg24084606 ( $p = 1.3e-9$ ) (**Fig. 4A**). To determine whether the effect of DNA  
14 methylation can be modified by the APOE4 allele, we performed conditional analysis by including  
15 the APOE2,3,4 defining SNPs as co-variates, and found the results were not influenced (**Fig. 4B**).  
16 We also checked for statistical interaction between methylation levels and AD alleles were  
17 influenced. As expected, we did not observe significant interactions between our candidate AD  
18 alleles and APOE4 on the DNA methylation levels (**Fig. 4C**). Consistent with the independent  
19 relationship, we found that APOE2,3,4 determining SNPs are not associated with our prioritized  
20 CpG methylation levels.

21  
22 ChIP-seq experiments can determine which chromatin regions are actively involved in gene  
23 transcription. Here we carried out several steps to prioritize SNPs within active chromatin at the  
24 *APOE* locus: First, we identified that rs157580 is located within active chromatin regions (**Fig.**  
25 **5A**). Second, most enhancers exert their regulatory function through the binding of TFs. Thus, we  
26 performed an in-silico search of the DNA sequence of the SNP for putative TF binding sites using  
27 Motif Scan and Enrichment Analysis (MoSEA). Third, we reviewed the literature and found motifs  
28 affected by SNPs that were reported to be involved in neuronal function. rs157580 was predicted  
29 to be located within binding sites of EGR4 and vitamin D receptor (VDR) (**Fig. 5B**).

30  
31 rs157580 is not significantly associated with global *APOE* levels in European and African  
32 populations across our datasets. However, they were associated with the jxn1.2.2 transcript (FDR  
33 < 0.05). While rs157580 is associated with jxn1.2.2 expression levels in European, it is also  
34 significantly associated with jxn1.2.2 expression levels in African, indicating the shared regulatory  
35 mechanisms for both ancestries. Importantly, rs157580 may represent partially independent  
36 meQTLs associated with AD risk, according to the weak linkage disequilibrium with the common  
37 AD-risk polymorphisms (rs7412 and rs429358 defining the APOE2,3,4 alleles, **Fig. 5C**).  
38 Furthermore, CSF Amyloid-beta 42 (A $\beta$ 42) and phosphorylated tau (pTau) are two major proteins  
39 implicated in the AD pathological process that can be assayed. We studied the genetic effects on  
40 CSF A $\beta$ 42 and pTau levels in a total of 13,116 individuals using GWAS data<sup>25</sup>. We found that  
41 rs157580 is associated with both biomarkers in CSF ( $p = 4.37e-74$  and  $1.97e-58$  separately)  
42 (**Supplementary Fig. S4**).

43

## 1 DISCUSSION

2 The APOE2,3,4 are not the only genetic risk factors for AD. Indeed, GWAS studies<sup>5</sup> have  
3 identified numerous potential AD risk SNPs. However, the molecular mechanism of most AD loci  
4 remains largely elusive. Despite *APOE* has long been a widely investigated gene since the  
5 identification of its association with lipid levels and AD, the biological mechanisms behind these  
6 associations are unknown. Many studies have reported the relationship between APOE2,3,4  
7 protein isoforms and AD-related traits, such as impairing synaptic repair and plasticity<sup>26</sup>;  
8 increasing beta-amyloid aggregation<sup>27-29</sup>; increasing formation of neurofibrillary tangles; and  
9 decreasing metabolic activity of neurons<sup>30</sup>. These phenotypes have been largely attributed to  
10 APOE2,3,4 protein isoform biochemical properties that differ by single amino acid substitutions  
11 constituted by alleles of rs7412 and rs429358<sup>31</sup>. Indeed, beyond the overt differential molecular  
12 bending of APOE2,3,4 isoforms and subsequent alterations in lipidation capacity<sup>32,33</sup>, there is  
13 limited evidence supporting functional variants at this locus modulating full-length APOE  
14 isoforms.

15  
16 Here, we provide evidence of additional functional elements at the *APOE* locus that may contribute  
17 to the mechanism of action of the *APOE* locus in AD and related phenotypes. We leveraged data  
18 from multiple large population-based cohorts of human postmortem brains in diverse ethnic groups.  
19 Our study offers insights into the genomics elements controlling *APOE* expression in the brain,  
20 but the pathological relevance of observed *APOE* transcripts by including/excluding exons and  
21 their regulatory mechanism will need additional clarifications in the future. Similar to our work in  
22 *SNX19*<sup>19</sup> and *CYP2D6*<sup>18</sup> genes, we demonstrate that a careful analysis of postmortem brain data  
23 can identify specific *APOE* gene transcription mechanisms associated with AD-risk alleles. Our  
24 results prioritize specific domains between exon 1 and exon 2 in the protein that contain the  
25 functional domain that might influence AD risk. The data made us aware that the AD susceptibility  
26 signals can also be masked in gene expression analysis, and that the focus on individual transcripts  
27 is absolutely crucial to understanding APOE mechanisms operating not only in the brain but also  
28 in other tissues expressing this pleiotropic gene. Furthermore, pinpointing additional functional  
29 mechanisms modulating causal common variants at the *APOE* region and elucidating their roles  
30 in AD susceptibility might contribute to delineating therapeutic strategies for controlling this  
31 important susceptibility factor. Unfortunately, controlling APOE-associated risk remains a major  
32 challenge of dementia research. Our results therefore refine our understanding of the *APOE* locus  
33 and suggest that genetic variant affecting APOE regulatory motifs might have independent effects  
34 influencing AD susceptibility.

35  
36 Strengths of this study include the use of the ROSMAP cohort in our main analyses, and extended  
37 in the LIBD cohort and its connection with large meta-GWAS of AD risk. The ROSMAP brain  
38 collections are unique in terms of their longitudinal nature, and in the ages of the subjects involved.  
39 This study is also strengthened by identifying the potential pathogenic role of *APOE* jxn1.2.2  
40 transcript, and replicating it in the additional cohort with different ancestry. Importantly, this  
41 transcript is also a risk expression feature in the African ancestry population. The *APOE* jxn1.2.2  
42 transcript was differentially expressed between AD and controls and in the DLPFC brain region.  
43 The DLPFC is a region affected by amyloid- $\beta$  pathology relatively early as it spreads throughout  
44 the neocortex<sup>34</sup>. The accumulation of tau pathology progresses stereotypically captured by the  
45 Braak stages<sup>35</sup>, and the DLPFC displays an accumulation of neurofibrillary tangles containing tau  
46 typically when individuals begin to be symptomatic. Thus, both pathological amyloid- $\beta$  and tau

1 accumulate in the DLPFC in AD, and we use quantitative measures of these pathologies to enhance  
2 our power in discovering the molecular features that are associated with these pathologies.  
3 However, we feel that characterizing more brain regions is very necessary to understand its  
4 potential role in AD pathogenesis and its connection with mature APOE protein isoforms.

5  
6 A major finding of this study is that the *APOE* jxn1.2.2 transcript might differentially contribute  
7 to AD risk compared to other alternative transcripts. We found that AD alleles are specifically  
8 associated with enhanced jxn1.2.2 expression. Consistently, we also found that upregulation of  
9 *APOE* jxn1.2.2 transcript is associated with AD hallmark NTF. Those findings support our  
10 hypothesis that AD-linked *APOE* transcript signals can be masked in analysis at the gene level.  
11 Because this transcript is partially affected by the APOE2,3,4 alleles, it might be an important  
12 additional factor within this *APOE* region. To the best of our knowledge, this is the first study to  
13 pinpoint this AD-linked *APOE* coding transcript. We propose that this transcript may be regulated  
14 by AD SNPs in a disease-state manner or could itself be driven by AD pathology. Long-read  
15 sequencing may be helpful to elucidate the full spectrum of the *APOE* transcripts in human brain  
16 tissue and human iPSC-derived brain organoids.

17  
18 Despite the wealth of evidence linking *APOE* SNPs to pathology implicated in AD, an  
19 understanding of the specific mechanism(s) by which genetic variation at this region alters risk  
20 remains incomplete. *APOE* acts in conjunction with other genetic and environmental factors to  
21 confer AD risk. DNA methylation and chromatin status are associated with genetic and  
22 environmental factors, and previous studies have identified associations with AD and  
23 neuropathological hallmarks of AD in large collections of human brain tissue samples<sup>36,37</sup>.  
24 However, DNA methylation at the *APOE* locus has not been well studied. We found *APOE* alleles  
25 associated with AD and associated simultaneously with methylation levels of cg24084606, which  
26 was also reported to be involved in the autism spectrum. However, there was a weak association  
27 in a South African Cohort<sup>38</sup>.

28  
29 Our data suggests that EGR4 and VDR might play a role during *APOE* gene transcription. EGR4,  
30 a zinc-finger transcription factor, is downregulated in AD mouse models' brain<sup>39</sup>. It plays an  
31 important role in the developmental upregulation of KCC2 gene expression that is essential for  
32 fast synaptic inhibition in adult neurons<sup>40</sup>. Vitamin D can upregulate VDR<sup>41</sup> and purportedly  
33 protect against cognitive decline and dementia<sup>42</sup>. However, the binding of one TF alone is rarely  
34 enough to directly infer functional effects on the gene expression levels, typically under the  
35 combinatorial and dynamic control of multiple TFs. Therefore, TF data are often actively  
36 integrated with other functional genomic techniques to decipher the basic regulatory control of  
37 gene expression, such as by incorporating active chromatin regions, DNA methylations, and SNPs.  
38 Interestingly, the SNP we prioritized is located within ChIP-seq peaks, correlated with CpG  
39 methylation levels, influences *APOE* jxn 1.2.2 transcript expression, and has genetic effects on  
40 AD core features in CSF (A $\beta$ 42 and pTau).

41  
42 Our study revealed new *APOE* gene regulatory mechanisms affecting common AD risk SNP that  
43 may interact with chromatin, TFs, and DNA methylation to be responsible for turning the *APOE*  
44 transcription on or off in a different set of cells, or at different times. Though we identified potential  
45 functional variant associated with AD in this study, we still do not know how this genetic control  
46 of gene expression confers AD risk and pathology. It is likely that the identified SNP affects the



1 *APOE* jxn1.2.2 expression level no matter the *APOE* genotype, and the change of *APOE* jxn1.2.2  
2 expression may play a pivotal role in neuropathogenesis. We plan to assess whether repression of  
3 jxn1.2.2 expression through CRISPR assays in human induced pluripotent stem cell lines derived  
4 from rs157580-A carriers modulate AD-relevant phenotypes. If validated, these cell lines could  
5 then serve as models to test molecules as potential therapeutic interventions for treating rs157580-  
6 A carriers by manipulating the gene expression of *APOE* jxn1.2.2. Finally, this work also  
7 highlights the importance of including different ancestries in research on AD, as shared functional  
8 elements can provide windows of opportunity to cure the disease in diverse populations.  
9

## 10 MATERIALS AND METHODS:

### 11 ROSMAP:

#### 12 WGS Data processing:

13 Whole-genome sequencing (WGS) datasets collected by the ROSMAP consortium were obtained  
14 from AD Knowledge Portal. There were 43,012,378 genomic variants in the raw data. Genetic  
15 variants were filtered out with PLINK 1.9<sup>43</sup> if they: (1) had a genotype missing rate > 10%; (2) had  
16 Minor Allele Frequencies (MAF) < 1%; and (3) deviated from Hardy–Weinberg Equilibrium  
17 (HWE,  $p$ -value < 1E-6). Finally, we retained 9,912,554 common single nucleotide  
18 polymorphisms (SNPs) (23% of the total genetic variants).

#### 19 IBD and PCA:

20 To detect genetically related samples and population stratification, we applied stricter Quality  
21 Control (QC) procedures before conducting the Identity-By-Decent (IBD) test and Principal  
22 Component Analysis (PCA). First, we merged the study data with HapMap3 data and kept only  
23 the overlapped SNPs. We then removed SNPs if they: (1) had a genotype missing rate > 1%; (2)  
24 had MAF < 5%; (3) deviated from HWE ( $p$ -value < 1E-3), and (4) were in Major  
25 Histocompatibility Complex (MHC) regions (chr6:25M-33.5M). Finally, we retained 995,871  
26 variants for further analysis. Pruning was conducted twice using PLINK with option --indep-  
27 pairwise 200 100 0.2. IBD test was conducted using PLINK with option --genome. Subjects with  
28 PI-HAT > 0.2 were identified as the related subjects, and one of the related subjects with a higher  
29 overall SNP missing rate of the pair was removed. PCA was conducted with EIGENSOFT 6.1.3<sup>44</sup>.  
30 Twenty PCs were kept. Outliers of the population were detected in a training-prediction approach.  
31 We classified HapMap3 samples into two groups: EUR (CEU, TSI) and others. Next, we used 20  
32 PCs of HapMap samples to fit a general linear model with glmnet, and then we used an estimated  
33 model to predict the probability of ancestry (ancestry score) for the studying sample. Subjects with  
34 ancestry scores lower than 0.8 were removed from study samples.

#### 35 Bulk brain RNA-Seq data processing:

36 Three brain regions of postmortem data were included in this study. The protocol of sample  
37 procurement has been described previously<sup>13,45</sup>. QC of the sequence data, including checks for  
38 over-abundance of adaptors and over-represented sequence, was performed using FastQC. Low-  
39 quality reads (5% of the total) were filtered out using the Trimmomatic<sup>46</sup>, which is a fast,  
40 multithreaded command line tool to trim and crop FASTQ data and remove adapters<sup>46</sup>. After  
41 trimming adapter sequences, reads passing initial QC were aligned to the human reference genome  
42 using HISAT2<sup>47</sup>. Gene lengths were calculated using GENCODE v41 annotations<sup>48</sup>. We converted  
43 gene counts to RPKM values using the total number of aligned reads across the 22 autosomal  
44 chromosomes. We converted junction counts to normalized values using the total number of

1 aligned reads across the autosomal chromosomes, which can be interpreted as the number of reads  
2 supporting the junction in an average library size<sup>15</sup>.

3 *cis*-acting eQTL analysis:

4 *cis*-eQTL association was examined separately by feature type (gene and junction) using  
5 TensorQTL package<sup>22</sup>, taking log<sub>2</sub>-transformed expression levels of each measurement (RPKM  
6 and RP10M) as the income. Features with low expression (average counts < 0.4 in gene and < 0.1  
7 in junction) were excluded before eQTL analysis. To control for potential confounding factors, we  
8 adjust for ancestry (first 5 PCs) from the genotype data, diagnosis, sex, and the first K PCs of the  
9 normalized expression features, where K was calculated separately by feature type using the sva  
10 Bioconductor package<sup>49</sup> (DLPFC: gene - 23 PCs, junction - 27 PCs). False discovery rate (FDR)  
11 was assessed across all *cis*-eQTL tests within each chromosome using R package qvalue<sup>50</sup>. We  
12 considered all variant–gene pairs (expression features to genes, eGene) and variant–junction pairs  
13 (eJunction) when the distance between features and SNP is <1MB.

14 Conditional analysis on APOE2,3,4 determining SNPs:

15 We evaluated the effects of *APOE* loci on associations of candidate SNPs with the expression of  
16 *APOE* and the corresponding junctions. Since we don't have data for *APOE4* diplotypes in the  
17 LIBD sample, we used two *APOE* SNPs (rs7412 and rs429358) as covariates in the model to  
18 investigate the conditional effect of *APOE2,3,4* alleles.

19  $fit0 = glm(expression \sim Dx + Age + Sex + RIN + rRNA\ rate + totalAssignedGene + 5\ SNP\ PCs$   
20  $+ K\ feature\ PCs + rs7412 + rs429358, data=candi)$

21  $Residual = resid(fit0)$

22  $fit1 = glm(residual \sim SNP, data=candi)$

23 If the p-values of candidate SNPs in fit1 keep significance as original models without two *APOE*  
24 SNPs, we concluded that the effect of candidate SNPs is independent with two *APOE* SNPs.

25 Epistasis of candidate SNPs and *APOE4* on expression:

26 We used a general linear model and likelihood ratio test to evaluate the epistasis between the  
27 *APOE4* haplotype and our candidate SNPs.

28  $Fit0 = glm(expression \sim Dx + Age + Sex + RIN + rRNA\ rate + totalAssignedGene + 5\ SNP\ PCs$   
29  $+ K\ feature\ PCs, data=candi)$

30  $Residual = resid(fit0)$

31  $fit1 = glm(residual \sim SNP + APOE4, data=candi)$

32  $fit2 = glm(residual \sim SNP * APOE4, data=candi)$

33  $lrtest(fit2, fit1)$

34 Results of the likelihood ratio test showed if there is an interaction effect of explanatory  
35 variables on response variables.

36 Differential Expression Analysis:

37 Since we focused on only *APOE* and the related junctions, we used a general linear model to  
38 investigate the differential expression in diagnosis groups. We first fit a general linear model using  
39 Sex, Age, RIN, rRNA-Rate, the total number of assigned genes, 5 SNP PCs, and K number gene  
40 PCs used in eQTL analysis to keep consistency. We took the residual as the adjusted expression  
41 levels for further examination. Using the adjusted expressions, we conducted an ANOVA test  
42 using Anova in R to evaluate the difference between diagnosis groups. We also used the adjusted  
43 expressions for the related plots.

44 □  $H_0: \mu_{control} = \mu_{case}$

1     □  $H_1$ : mean is different

2      $Fit0 = glm(expression \sim Age + Sex + RIN + rRNA\ rate + totalAssignedGene + 5\ SNP\ PCs + K$   
3      $feature\ PCs$

4      $Fit1 = glm(residual \sim Dx)$

5      $Result = Anova(fit)$

6     DNA Methylation Data processing:

7     Methylation data was created on prefrontal cortex samples collected from 743 individuals using  
8     the Illumina HumanMethylation450 BeadChip by the ROSMAP consortium. After matching to  
9     QCed genotype data, we got 667 samples. QC and normalization were conducted using minfi R  
10    package<sup>51</sup>. Failed positions were identified with detectionP function in minfi by examining both  
11    the methylated and unmethylated channel reporting background signal levels. P-value for every  
12    genomic position in every sample was estimated. Small p-values indicate a good position. We  
13    excluded samples with averaged p-values > 0.05 across all probes, and also removed probes with  
14    averaged p-values > 0.05 across all samples. Normalization was conducted with function  
15    preprocessQuantile. We excluded probes on sex chromosomes to focus on mQTLs analysis on  
16    autosome chromosomes. We also removed probes that have the same locations as SNPs.

17    mQTL analysis:

18    *cis*-mQTL association was examined for CpG using TensorQTL package<sup>22</sup>. To control for  
19    potential confounding factors, we adjusted for ancestry using the first five PCs from the genotype  
20    data, sex, and the first 2 Negative control PCs that were calculated with R Bioconductor package  
21    sva<sup>21</sup> using QCed methylation data. FDR was assessed in R package qvalue<sup>50</sup> across all QTL tests  
22    within each chromosome. We considered all variant–CpG pairs when the distance between CpG  
23    and SNP is <1MB.

24    ChIP-Seq data processing:

25    Trim Galore was used to check the quality of the FASTQ files and run trimming. Bowtie 2 was  
26    used to align FASTQ files while the output was converted to the SAM file format. Samtools view  
27    was used to convert SAM files to BAM format. Bedtools intersect function was used to remove  
28    chrM, chrUN, pcr dup done with parameters, where blacklist is a list of unwanted sequences from  
29    the human reference genome. This output was then sorted using Samtools sort and potential PCR  
30    duplicates were removed using Samtools rmdup. To create bigWig file formats, deepTools  
31    bamCoverage was used. To obtain DNA binding motifs, we used Motif Scan and Enrichment  
32    Analysis (MoSEA) to scan for motifs. MoSEA can search for motifs against specified position  
33    weight matrices (PWMs). We used the HOMO sapiens COMPREHENSIVE MODEL COLLECTION  
34    (HOCOMOCO) v11 mononucleotide in MEME format as the PWMs. MoSEA also incorporates  
35    MEME Suite's Find Individual Motif Occurrences (FIMO)<sup>52</sup> tool to scan for sets of sequences for  
36    individual matches to all motifs in HOCOMOCO v11<sup>53</sup>.

37    LIBD

38    Genotype Data processing:

39    SNP genotyping with HumanHap650Y\_V3, Human 1M-Duo\_V3, and Omni5 BeadChips  
40    (Illumina, San Diego, CA) was conducted with DNA extracted from brain cerebellar tissue.  
41    Genotype imputation was performed on TOPMed server with the imputation reference from the  
42    Human Reference Forum (<https://topmedimpute.readthedocs.io/en/latest/>). We retained common  
43    SNPs (MAF > 5%) that were present in the majority of samples (missingness < 5%) that were  
44    in HWE (p-value >  $1 \times 10^{-6}$ ) using the PLINK 1.9<sup>43</sup>. 9,984,191 SNPs were retained after QC.

1 Bulk brain RNA-Seq data processing:

2 DLPFC RNA-Seq data from postmortem brain samples were included in this study. Details of  
3 tissue acquisition, handling, processing, dissection, clinical characterization, diagnoses,  
4 neuropathological examinations, RNA extraction, and quality control measures were described  
5 previously<sup>54</sup>. RNA extraction, sequencing, and RNA data processing were also described  
6 previously<sup>15</sup>. In our analysis, gene lengths were calculated using GENCODE v41 annotations<sup>48</sup>.  
7 We normalized gene counts and junction counts using the same approach as we did for ROSMAP  
8 data.

9 Cis-eQTLs analysis:

10 *cis*-eQTL association was examined using TensorQTL package<sup>22</sup>, taking log<sub>2</sub>-transformed  
11 expression levels of each measurement (RPKM and RP10M) as the income. Features with low  
12 expression (average counts < 0.4 in gene and < 0.1 in junction) were excluded before eQTL  
13 analysis. To control for potential confounding factors, we adjust for ancestry (first five PCs from  
14 the genotype data), diagnosis, sex, and the first K PCs of the normalized expression features, where  
15 K was calculated separately by feature type using the sva Bioconductor package<sup>49</sup> (AA: gene - 16,  
16 junction - 13).

17 **ACKNOWLEDGEMENTS:**

18 The ROSMAP was supported by the National Institute on Aging (NIA) RF1AG57473,  
19 P30AG010161, R01AG015819, R01AG017917, U01AG46152, U01AG61356, RF1AG059082,  
20 P30AG072975, and R01AG036042. The authors would like to acknowledge NIA P30AG066546,  
21 U01 AG058589, R01 AG061872, U01 AG052409, R01 AG059421. The authors also  
22 acknowledge Bill and Rebecca Reed Endowment for Precision and Palliative Medicine. We  
23 acknowledge the Texas Advanced Computing Center (TACC) and Genomics, Epigenomics,  
24 Network, Imaging, and Education (GENIE) for providing high-performance computing (HPC)  
25 resources.

26

27

28

## 1 REFERENCES

- 2 1. Reardon S. FDA approves Alzheimer's drug lecanemab amid safety concerns. 2023;  
3 *Nature* **613**: 227-228.
- 4 2. Alzheimer's Association. 2018 Alzheimer's disease facts and figures. 2018; *Alzheimer's*  
5 *& Dementia* **367**–429.
- 6 3. Rajan KB, Weuve J, Barnes LL, Wilson RS, Evans DA. Prevalence and incidence of  
7 clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population  
8 study. 2019; *Alzheimers Dement* **15**: 1-7. PMC6531287
- 9 4. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW *et al.*  
10 Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late  
11 onset families. 1993; *Science* **261**: 921-923.
- 12 5. de Rojas I, Moreno-Grau S, Tesi N, Grenier-Boley B, Andrade V, Jansen IE *et al.*  
13 Common variants in Alzheimer's disease and risk stratification by polygenic risk scores.  
14 2021; *Nat Commun* **12**: 3417. PMC8184987
- 15 6. Zhang A, Zhao Q, Xu D, Jiang S. Brain APOE expression quantitative trait loci-based  
16 association study identified one susceptibility locus for Alzheimer's disease by interacting  
17 with APOE epsilon4. 2018; *Sci Rep* **8**: 8068. PMC5966425
- 18 7. He L, Loika Y, Kulminski AM. Allele-specific analysis reveals exon- and cell-type-  
19 specific regulatory effects of Alzheimer's disease-associated genetic variants. 2022;  
20 *Transl Psychiatry* **12**: 163. PMC9016079
- 21 8. Xu Q, Walker D, Bernardo A, Brodbeck J, Balestra ME, Huang Y. Intron-3  
22 retention/splicing controls neuronal expression of apolipoprotein E in the CNS. 2008; *J*  
23 *Neurosci* **28**: 1452-1459. PMC6671590
- 24 9. Chen Z, Zhang D, Reynolds RH, Gustavsson EK, Garcia-Ruiz S, D'Sa K *et al.* Human-  
25 lineage-specific genomic elements are associated with neurodegenerative disease and  
26 APOE transcript usage. 2021; *Nat Commun* **12**: 2076. PMC8024253
- 27 10. Mills JD, Sheahan PJ, Lai D, Kril JJ, Janitz M, Sutherland GT. The alternative splicing of  
28 the apolipoprotein E gene is unperturbed in the brains of Alzheimer's disease patients.  
29 2014; *Mol Biol Rep* **41**: 6365-6376.
- 30 11. Foraker J, Millard SP, Leong L, Thomson Z, Chen S, Keene CD *et al.* The APOE Gene is  
31 Differentially Methylated in Alzheimer's Disease. 2015; *J Alzheimers Dis* **48**: 745-755.  
32 PMC6469491
- 33 12. Yu CE, Foraker J. Erratum to: Epigenetic considerations of the APOE gene. 2015;  
34 *Biomol Concepts* **6**: 235.
- 35 13. De Jager PL, Ma Y, McCabe C, Xu J, Vardarajan BN, Felsky D *et al.* A multi-omic atlas  
36 of the human frontal cortex for aging and Alzheimer's disease research. 2018; *Sci Data* **5**:  
37 180142. PMC6080491
- 38 14. BrainSeq AHBGCeadlo, BrainSeq AHBGC. BrainSeq: Neurogenomics to Drive Novel  
39 Target Discovery for Neuropsychiatric Disorders. 2015; *Neuron* **88**: 1078-1083.
- 40 15. Jaffe AE, Straub RE, Shin JH, Tao R, Gao Y, Collado-Torres L *et al.* Developmental and  
41 genetic regulation of the human cortex transcriptome illuminate schizophrenia  
42 pathogenesis. 2018; *Nat Neurosci* **21**: 1117-1125. PMC6438700
- 43 16. Ng B, White CC, Klein HU, Sieberts SK, McCabe C, Patrick E *et al.* An xQTL map  
44 integrates the genetic architecture of the human brain's transcriptome and epigenome.  
45 2017; *Nat Neurosci* **20**: 1418-1426. PMC5785926

- 1 17. Laverre A, Tannier E, Necsulea A. Long-range promoter-enhancer contacts are  
2 conserved during evolution and contribute to gene expression robustness. 2022; *Genome*  
3 *Res* **32**: 280-296. PMC8805723
- 4 18. Ma L, Shcherbina A, Chetty S. Variations and expression features of CYP2D6 contribute  
5 to schizophrenia risk. 2021; *Mol Psychiatry* **26**: 2605-2615. PMC8440189
- 6 19. Ma L, Semick SA, Chen Q, Li C, Tao R, Price AJ *et al*. Schizophrenia risk variants  
7 influence multiple classes of transcripts of sorting nexin 19 (SNX19). 2020; *Mol*  
8 *Psychiatry* **25**: 831-843.
- 9 20. Ma L, Jia P, Zhao Z. Splicing QTL of human adipose-related traits. 2018; *Sci Rep* **8**: 318.  
10 PMC5762880
- 11 21. Leek JT, Storey JD. Capturing heterogeneity in gene expression studies by surrogate  
12 variable analysis. 2007; *PLoS Genet* **3**: 1724-1735. PMC1994707
- 13 22. Taylor-Weiner A, Aguet F, Haradhvala NJ, Gosai S, Anand S, Kim J *et al*. Scaling  
14 computational genomics to millions of individuals with GPUs. 2019; *Genome Biol* **20**:  
15 228. PMC6823959
- 16 23. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC *et al*.  
17 Neuropathology of older persons without cognitive impairment from two community-  
18 based studies. 2006; *Neurology* **66**: 1837-1844.
- 19 24. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. 1991; *Acta*  
20 *Neuropathol* **82**: 239-259.
- 21 25. Jansen IE, van der Lee SJ, Gomez-Fonseca D, de Rojas I, Dalmaso MC, Grenier-Boley  
22 B *et al*. Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid  
23 biomarkers. 2022; *Acta Neuropathol* **144**: 821-842. PMC9547780
- 24 26. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential  
25 effects of apolipoproteins E3 and E4 on neuronal growth in vitro. 1994; *Science* **264**:  
26 850-852.
- 27 27. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ *et al*.  
28 Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a  
29 mouse model of Alzheimer's disease. 2000; *Proc Natl Acad Sci U S A* **97**: 2892-2897.  
30 PMC16026
- 31 28. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW *et al*. Human  
32 apoE isoforms differentially regulate brain amyloid-beta peptide clearance. 2011; *Sci*  
33 *Transl Med* **3**: 89ra57. PMC3192364
- 34 29. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH *et al*.  
35 Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of  
36 apolipoprotein E genotype in late-onset Alzheimer disease. 1993; *Proc Natl Acad Sci U S*  
37 *A* **90**: 9649-9653. PMC47627
- 38 30. Qiu Z, Crutcher KA, Hyman BT, Rebeck GW. ApoE isoforms affect neuronal N-methyl-  
39 D-aspartate calcium responses and toxicity via receptor-mediated processes. 2003;  
40 *Neuroscience* **122**: 291-303.
- 41 31. Minta K, Brinkmalm G, Janelidze S, Sjodin S, Portelius E, Stomrud E *et al*.  
42 Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from  
43 patients with neurodegenerative diseases. 2020; *Alzheimers Res Ther* **12**: 19.  
44 PMC7020540

- 1 32. Frieden C, Wang H, Ho CMW. A mechanism for lipid binding to apoE and the role of  
2 intrinsically disordered regions coupled to domain-domain interactions. 2017; *Proc Natl*  
3 *Acad Sci U S A* **114**: 6292-6297. PMC5474821
- 4 33. Lanfranco MF, Ng CA, Rebeck GW. ApoE Lipidation as a Therapeutic Target in  
5 Alzheimer's Disease. 2020; *Int J Mol Sci* **21**. PMC7503657
- 6 34. Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP *et*  
7 *al.* Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation  
8 in AD brain. 2004; *Neurology* **62**: 925-931.
- 9 35. Guillozet AL, Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid,  
10 and memory in aging and mild cognitive impairment. 2003; *Arch Neurol* **60**: 729-736.
- 11 36. De Jager PL, Srivastava G, Lunnon K, Burgess J, Schalkwyk LC, Yu L *et al.* Alzheimer's  
12 disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other  
13 loci. 2014; *Nat Neurosci* **17**: 1156-1163. PMC4292795
- 14 37. Palma-Gudiel H, Yu L, Huo Z, Yang J, Wang Y, Gu T *et al.* Fine-mapping and  
15 replication of EWAS loci harboring putative epigenetic alterations associated with AD  
16 neuropathology in a large collection of human brain tissue samples. 2023; *Alzheimers*  
17 *Dement* **19**: 1216-1226. PMC9922334
- 18 38. Stathopoulos S, Gaujoux R, Lindeque Z, Mahony C, Van Der Colff R, Van Der  
19 Westhuizen F *et al.* DNA Methylation Associated with Mitochondrial Dysfunction in a  
20 South African Autism Spectrum Disorder Cohort. 2020; *Autism Res* **13**: 1079-1093.  
21 PMC7496548
- 22 39. Castillo E, Leon J, Mazzei G, Abolhassani N, Haruyama N, Saito T *et al.* Comparative  
23 profiling of cortical gene expression in Alzheimer's disease patients and mouse models  
24 demonstrates a link between amyloidosis and neuroinflammation. 2017; *Sci Rep* **7**:  
25 17762. PMC5736730
- 26 40. Uvarov P, Ludwig A, Markkanen M, Rivera C, Airaksinen MS. Upregulation of the  
27 neuron-specific K<sup>+</sup>/Cl<sup>-</sup> cotransporter expression by transcription factor early growth  
28 response 4. 2006; *J Neurosci* **26**: 13463-13473. PMC6674722
- 29 41. Supriya M, Chandra SR, Prabhakar P, Prasad C, Christopher R. Vitamin D receptor  
30 (VDR) gene polymorphism and vascular dementia due to cerebral small vessel disease in  
31 an Asian Indian cohort. 2018; *J Neurol Sci* **391**: 84-89.
- 32 42. Shea MK, Barger K, Dawson-Hughes B, Leurgans SE, Fu X, James BD *et al.* Brain  
33 vitamin D forms, cognitive decline, and neuropathology in community-dwelling older  
34 adults. 2023; *Alzheimers Dement* **19**: 2389-2396. PMC10244481
- 35 43. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation  
36 PLINK: rising to the challenge of larger and richer datasets. 2015; *Gigascience* **4**: 7.  
37 PMC4342193
- 38 44. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal  
39 components analysis corrects for stratification in genome-wide association studies. 2006;  
40 *Nat Genet* **38**: 904-909.
- 41 45. Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA. Religious  
42 Orders Study and Rush Memory and Aging Project. 2018; *J Alzheimers Dis* **64**: S161-  
43 S189. PMC6380522
- 44 46. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence  
45 data. 2014; *Bioinformatics* **30**: 2114-2120. PMC4103590

- 1 47. Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and  
2 genotyping with HISAT2 and HISAT-genotype. 2019; *Nat Biotechnol* **37**: 907-915.  
3 PMC7605509
- 4 48. Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F *et al.*  
5 GENCODE: the reference human genome annotation for The ENCODE Project. 2012;  
6 *Genome Res* **22**: 1760-1774. PMC3431492
- 7 49. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing  
8 batch effects and other unwanted variation in high-throughput experiments. 2012;  
9 *Bioinformatics* **28**: 882-883. PMC3307112
- 10 50. Storey JD BA, Dabney A, Robinson D. qvalue: Q-value estimation for false discovery  
11 rate control. Bioconductor 3.15 edn2022.
- 12 51. Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD *et al.*  
13 Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium  
14 DNA methylation microarrays. 2014; *Bioinformatics* **30**: 1363-1369. PMC4016708
- 15 52. Grant CE, Bailey TL, Noble WS. FIMO: scanning for occurrences of a given motif.  
16 2011; *Bioinformatics* **27**: 1017-1018. PMC3065696
- 17 53. Kulakovskiy IV, Vorontsov IE, Yevshin IS, Sharipov RN, Fedorova AD, Rumynskiy EI  
18 *et al.* HOCOMOCO: towards a complete collection of transcription factor binding models  
19 for human and mouse via large-scale ChIP-Seq analysis. 2018; *Nucleic Acids Res* **46**:  
20 D252-D259. PMC5753240
- 21 54. Lipska BK, Deep-Soboslay A, Weickert CS, Hyde TM, Martin CE, Herman MM *et al.*  
22 Critical factors in gene expression in postmortem human brain: Focus on studies in  
23 schizophrenia. 2006; *Biol Psychiatry* **60**: 650-658.  
24






Figure 1. Overview of APOE study in human postmortem brain (A) and novel AD functional elements (genetic, transcriptomic, and epigenetic elements) and their relative position at the APOE locus (B). Brain collection: ROSMAP, The Religious Orders Study and the Memory and Aging Project; LIBD, Lieber Institute for Brain Development. Ancestry: EA, European Ancestry; AA, African American. Brain region: DLPFC, dorsolateral prefrontal cortex.




Figure 2. APOE jxn 1.2.2 transcript is associated with Alzheimer's disease (AD). (A) jxn1.2.2 expression (red) is the top hit compared to other transcripts at the APOE locus (blue). (B) The association of AD risk SNP, rs157580, with APOE gene level and its 3 transcripts (jxn1.2.1, jxn1.2.2, and jxn1.2.3) in ROSMAP European ancestry. (C) Association of jxn1.2.2 and AD risk SNP in LIBD African American (AA).




Figure 3. Differential expression of APOE at the gene level and transcripts level between AD and controls in BRAAK diagnosis.




Figure 4. Genotypic impact of rs157580 on DNA methylation levels of cg24084606 in ROSMAP DLPFC brain tissue. (A) Association of the candidate AD risk SNPs with CpG sites. (B) The association of the AD-allele-linked CpGs is not affected by the APOE4 allele by Conditional analysis. (C) No interaction between APOE4 and rs157580 on DNA methylation levels.







Figure 5. rs157580 is located within active chromatin and affects transcriptional factors (TFs)' binding affinity. (A) rs157580 is co-localized with H3K9ac ChIP-seq peak from human postmortem brains. (B) Recognition sites of TFs involved in Alzheimer's disease are influenced by rs157580. The red dash box indicates the binding site of each SNP. (C) Linkage disequilibrium of rs157580 with other SNPs spanning APOE, including the two APOE2,3,4-determining SNPs.



Supplementary Figure S1. GWAS summary statistics at the APOE locus (hg38, chr19:44,655,791–45,159,393). Color is coded for linkage disequilibrium of predicted functional SNP rs157580 and SNPs consisting of APOE2,3,4 genotypes (rs429358 and rs7412). Minimum p-value =  $1e-300$ .




Supplementary Figure S2. Principal component analysis (PCA) for (A) HapMap populations (reference), (B) ROSMAP European ancestry. (C) PC plots after removing outliers. (D) The ancestry score shows our populations are homogenous after removing outliers.



Supplementary Figure S3. Conditional analysis of APOE expression features with rs157580. EA, European ancestry; AA, African American





Supplementary Figure S4. A-beta protein GWAS summary statistics at the APOE locus (hg38, chr19:44,655,791–45,159,393). Color is coded for linkage disequilibrium of predicted functional SNP rs157580 and SNPs consisting of APOE2,3,4 genotypes (rs429358 and rs7412). Minimum p-value =  $1e^{-321}$ .

Supplementary Table S1. The association between rs157580 and APOE transcripts is not influenced by APOE2 and APOE4 genotypes

<b>SNP</b>	<b>Transcript</b>	<b>p-value</b>	<b>FDR</b>	<b>p-value (SNP X APOE4)</b>	<b>p-value (SNP X APOE2)</b>
rs157580	Jxn1.2.1	0.2685	0.9937	0.9195	0.1894
rs157580	Jxn1.2.2	1.71E-13	5.28E-10	0.1569	0.6391
rs157580	Jxn1.2.3	0.4621	0.9360	0.5110	0.3401
rs429358	Jxn1.2.1	0.5241	0.9937	-	-
rs7412	Jxn1.2.1	0.5720	0.9937	-	-
rs429358	Jxn1.2.2	1.99E-04	0.0228	-	-
rs7412	Jxn1.2.2	0.0827	0.6425	-	-
rs429358	Jxn1.2.3	0.1948	0.8044	-	-
rs7412	Jxn1.2.3	0.0927	0.7609	-	-

**NOTE:**

rs429358 and rs7412 are APOE2,3,4-determining SNPs.  
Data is from ROSMAP DLPFC brain region.